Table 2b.
Association between bone marrow fibrosis grade and patient characteristics
| Variable | n (%) | p value | |
|---|---|---|---|
| Grade 0, 1 | Grade 2 | ||
| Sex | |||
| Female | 22 (88) | 3 (12) | 0.37 |
| Male | 44 (77) | 13 (23) | |
| Race | |||
| Non-white | 3 (83) | 1 (50) | 0.61 |
| White | 36 (80) | 9 (20) | |
| Hepatomegaly | |||
| Yes | 2 (50) | 2 (50) | |
| No | 64 (82) | 14 (18) | 0.17 |
| Splenomegaly | |||
| Yes | 11 (73) | 4 (27) | |
| No | 54 (82) | 12 (18) | 0.48 |
| Transfusion dependency | |||
| Yes | 22 (69) | 10 (31) | |
| No | 40 (87) | 6 (13) | 0.09 |
| Treatment | |||
| HMA | 15 (79) | 4 (21) | 0.86 |
| HMA + combination | 10 (77) | 3 (23) | |
| TKI | 1 (100) | 0 (0) | |
| Chemotherapy | 11 (92) | 1 (8) | |
| Supportive therapy | 29 (78) | 8 (22) | |
| IPSS cytogenetic risk group | 0.51 | ||
| Poor | 5 (71) | 2 (29) | |
| Intermediate | 11 (73) | 4(27) | |
| Good or very good | 50 (83) | 10 (17) | |
Abbreviations: HMA=Hypomethylating agents, TKI=Tyrosine kinase inhibitors